Takeda expands in the United Arab Emirates
pharmafile | April 7, 2015 | News story | Medical Communications, Sales and Marketing | Dubai, NEMEA, Singapore, Takeda, UAE, United Arab Emirates, near east
Takeda has opened new UAE offices in Dubai amidst plans to expand its business in the Middle East.
The Japanese pharma giant says that the UAE will be a key growth driver for the company in the coming years. The firm has already more than tripled its revenue over the last decade in the region.
“The opening of Takeda’s office in the United Arab Emirates reflects our growing commitment to the UAE,” says Danilo Cassani, Takeda’s area head for Near East, Middle East, Turkey and Africa (NEMEA).
Speaking at the inauguration ceremony he continued: “We have ambitious plans in the NEMEA region and we continue to evaluate opportunities to establish Takeda as a key player in the area.”
Takeda only last month unveiled its plans to set up new offices in Singapore to allow it to focus on educational initiatives, collaboration with commercial teams plus clinical development activities.
The offices in the Biopolis biomedical complex in the Southeast Asian country will also play host to the Takeda vaccine business unit and a regional R&D centre. In Dubai, Takeda’s new office-space is located at Tecom IRise Tower.
Cassani says: “Patients are at the core of everything we do at Takeda, and we look forward to building on our established portfolio with an innovative pipeline of medicines in critical treatment areas – such as cardiovascular metabolic, gastroenterology and oncology – to meet the diverse healthcare needs of the Middle East.”
Ahdy ElSayes, who is the managing director for the company in the region, adds: “The UAE is one of the key countries for Takeda in the Middle East and it was a strategic decision to open our new office in UAE to allow a synergistic and convenient access to other key countries in the area.
“The healthcare system is a gateway for a growing pharma market supported by excellent economic indices.”
Takeda – whose new chief executive stepped into his role this month – has invested in research for a number of conditions in the region including four treatments aimed at acid reflux disease, oncology, diabetes and high blood pressure.
ElSayes concludes: “With an exciting pipeline of developed drugs ready for launch specific to these four treatment areas within the next five years, Takeda is ready and in a well-position to address the alarmingly rising incidence of these diseases in the Middle East region.”
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
